Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.

British journal of haematology·2026
Same author

Assays for Measuring the Cell Permeability of Proteolysis-Targeting Chimeras (PROTACs): Performance, Correlations, Applicability and Recommendations.

Molecular pharmaceutics·2026
Same author

Non-destructive transcriptomics via vesicular export.

Nature communications·2026
Same author

Advancing Reproducibility and Open Data in Theoretical and Computational Chemistry.

Journal of chemical theory and computation·2026
Same author

Relating Model Performance to Embedding Distributions in Molecular Machine Learning.

Journal of chemical information and modeling·2026
Same author

The Binding of 3-O-Methylfluorescein Phosphate to the Catalytic Domain of the Human CDC25B Phosphatase: A Structural Investigation.

Chembiochem : a European journal of chemical biology·2026

Related Experiment Video

Updated: Jul 6, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.4K

Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex.

Fabian Giehler1,2,3, Michael S Ostertag4, Thomas Sommermann5

  • 1Research Unit Signaling and Translation, Helmholtz Center Munich - German Research Center for Environmental Health, 85764, Neuherberg, Germany.

Nature Communications
|January 9, 2024
PubMed
Summary

Epstein-Barr virus (EBV) protein LMP1 directly recruits TRAF6 for B cell transformation. Targeting this LMP1-TRAF6 interaction may offer new therapies for EBV-associated cancers.

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.9K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Related Experiment Videos

Last Updated: Jul 6, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.4K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.9K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Area of Science:

  • Virology
  • Molecular Biology
  • Oncology

Background:

  • Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and cancer development.
  • LMP1's oncogenic functions rely on its C-terminal activation region 2 (CTAR2), which activates NF-κB and JNK signaling pathways.
  • The precise mechanism of TNF receptor-associated factor 6 (TRAF6) recruitment to LMP1 and its role in LMP1 signaling have remained unclear.

Purpose of the Study:

  • To elucidate the mechanism by which TRAF6 is recruited to LMP1.
  • To investigate the structural basis of the LMP1-TRAF6 interaction.
  • To determine the functional significance of the LMP1-TRAF6 complex in EBV-driven lymphomagenesis and explore its therapeutic potential.

Main Methods:

  • Direct interaction studies between LMP1 and TRAF6 using a viral TRAF6 binding motif within CTAR2.
  • Functional assays and Nuclear Magnetic Resonance (NMR) spectroscopy to analyze the LMP1-TRAF6 complex architecture.
  • Molecular modeling to provide structural insights.
  • Inhibition studies using peptides targeting the LMP1-TRAF6 complex in EBV-transformed B cells.

Main Results:

  • Demonstrated direct interaction between TRAF6 and a specific motif in LMP1's CTAR2.
  • Elucidated the distinct structural architecture of the LMP1-TRAF6 complex compared to CD40-TRAF6.
  • Confirmed that TRAF6 recruitment to LMP1 is essential for NF-κB activation and the survival of LMP1-driven lymphomas.
  • Showed that disrupting the LMP1-TRAF6 complex with inhibitory peptides reduces the viability of EBV-transformed B cells.

Conclusions:

  • Identified a direct LMP1-TRAF6 interaction mediated by a viral motif in CTAR2.
  • Established the LMP1-TRAF6 complex as a critical virus-host interface.
  • Validated the LMP1-TRAF6 interaction as a promising therapeutic target for EBV-associated cancers.